Overview
Organized and delivered in collaboration with the Dutch Medicines Evaluation Board (MEB), this face-to-face training course covers the major pharmacovigilance processes as outlined in GVP I to XVI. It is designed to provide a strong foundation in all key aspects of European Post-Marketing Safety regulatory requirements.
Furthermore, it includes highlights and updates on the pharmacovigilance legislation as well as the latest news on the ICH activities in pharmacovigilance.
Program Committee
-
Wendy Huisman, PharmD Director
Vigifit, Netherlands -
Fakhredin Sayed Tabatabaei, MD, PhD Senior Assessor
MEB, Netherlands
Have an account?